Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Center Trial of Desirudin for the Prophylaxis of Thrombosis: an Alternative to Heparin-Based Anticoagulation (DESIR-ABLE)

NCT00913133 is registered in ClinicalTrials.gov with Canyon Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00913133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00913133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Center Trial of Desirudin for the Prophylaxis of Thrombosis: an Alternative to Heparin-Based Anticoagulation (DESIR-ABLE)
Lead sponsor
Canyon Pharmaceuticals, Inc.
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2010
Completion date
June 30, 2011
Enrollment
516 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

thrombosis